secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001809519-24-000213
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx appoints Wendy Barnes as CEO and President, effective Jan 1, 2025
------------------------------------------------------------------------

- Wendy Barnes named CEO/President, succeeding interim CEO Scott Wagner; also elected Class I director.
- Base salary of $825,000, target bonus 100% of salary, and a $550,000 signing bonus.
- Equity grants: $9M RSU, $9M option, and $2M additional RSU, vesting over time.
- Severance: 12-18 months base salary plus COBRA for 18 months, with accelerated vesting on change of control.
- Barnes previously CEO of RxBenefits and President of Express Scripts; holds biochemistry degree.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000213/0001809519-24-000213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000213/gdrx-20241212.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer